healthcare analysts raised annual sales forecast weight loss drugs around 50 150 billion early 2030s one tells reuters medications including wugovie novo nordisk zepbown eli lilly captured imagination millions people insurers cover new therapies low copayments unprecedented percentage people paying coupons drug manufacturers analysts said recent data showing selfinjected drugs help stave costly emergencies like heart attack stroke treat chronic conditions like sleep apnea could lead employers insurers pay analysts say shortages cap sales 2023 though manufacturers increasing production sales new medications us list prices 1000 month lifted lilly novo ranks worlds valuable companies shares lilly 36 far year novo gained 33 one analyst says least 80 experimental obesity drugs reached human testing stage